What is HC Wainwright’s Forecast for Valneva Q3 Earnings?

Valneva SE Sponsored ADR (NASDAQ:VALN) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Valneva in a research report issued to clients and investors on Tuesday, August 19th. HC Wainwright analyst B. Folkes expects that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.73 EPS, FY2028 earnings at $1.68 EPS and FY2029 earnings at $1.98 EPS.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.11. The company had revenue of $54.84 million for the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%.

Separately, Guggenheim decreased their price objective on Valneva from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $16.00.

Valneva Price Performance

Shares of VALN stock opened at $11.50 on Thursday. Valneva has a twelve month low of $3.62 and a twelve month high of $12.25. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock has a fifty day simple moving average of $7.20 and a two-hundred day simple moving average of $6.88. The stock has a market capitalization of $978.54 million, a price-to-earnings ratio of -11.73 and a beta of 1.77.

Institutional Investors Weigh In On Valneva

A number of hedge funds have recently made changes to their positions in VALN. Marex Group plc bought a new stake in Valneva during the second quarter valued at about $64,000. GAMMA Investing LLC bought a new position in Valneva in the first quarter worth about $94,000. Wells Fargo & Company MN lifted its position in shares of Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after buying an additional 30,859 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. bought a new stake in shares of Valneva in the 2nd quarter valued at about $8,240,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.